National Bank of Canada
NVCR icon

National Bank of Canada’s NovoCure NVCR Stock Holding History

National Bank of Canada’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.66K Buy
244
+192
+369% +$2.4K ﹤0.01% 2576
2025
Q4 		$672 Sell
52
-224
-81% -$2.88K ﹤0.01% 2669
2025
Q3 		$3.57K Buy
+276
New +$3.69K ﹤0.01% 2508
2025
Q1 		– Sell
-2
Closed -$60 – 3062
2024
Q4 		$60 Sell
2
-45
-96% -$952 ﹤0.01% 2823
2024
Q3 		$735 Buy
+47
New +$852 ﹤0.01% 2457
2024
Q2 		– Sell
-233,000
Closed -$3.84M – 2788
2024
Q1 		$3.84M Buy
+233,000
New +$3.43M 0.01% 870
2023
Q4 		– Sell
-200
Closed -$3.09K – 2839
2023
Q3 		$3.09K Hold
200
– – ﹤0.01% 2449
2023
Q2 		$8.29K Sell
200
-327
-62% -$20.3K ﹤0.01% 2234
2023
Q1 		$31.7K Sell
527
-5
-0.9% -$400 ﹤0.01% 1845
2022
Q4 		$39K Buy
532
+15
+3% +$1.13K ﹤0.01% 1808
2022
Q3 		$39K Hold
517
– – ﹤0.01% 1778
2022
Q2 		$36K Buy
517
+34
+7% +$2.56K ﹤0.01% 1861
2022
Q1 		$40K Hold
483
– – ﹤0.01% 1949
2021
Q4 		$36K Buy
+483
New +$48.5K ﹤0.01% 1984

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

National Bank of Canada's NVCR Position: Q1 2026 in Review

National Bank of Canada increased its NovoCure (NVCR) stake by 369% in Q1 2026, buying an estimated $2.4K and bringing the position to 244 shares worth $2.66K. The position accounts for ﹤0.01% of the portfolio, ranked #2576.

National Bank of Canada first reported a position in NVCR in Q4 2021 and has held it in 14 quarters since. The position peaked at $3.84M in Q1 2024. 223 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • National Bank of Canada held 244 shares of NovoCure worth $2.66K as of Q1 2026.
  • National Bank of Canada bought 192 NovoCure shares in Q1 2026, an estimated $2.4K.
  • NovoCure made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2576 holding.
  • National Bank of Canada first reported a position in NovoCure in Q4 2021 and has held it in 14 quarters since.
  • National Bank of Canada's NovoCure position peaked at $3.84M in Q1 2024.
  • 223 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.